Pfizer, Arvinas win $85M upfront in Rigel licensing pact for new breast cancer med Veppanu

The deal includes up to $320 million in future milestone payments plus tiered royalties on Veppanu sales, which will be split evenly between Arvinas and Pfizer.

Nội dung đang được cập nhật.